Magnus IA, Jarret A, Prankerd TA, Rimington C. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet. 1961;2(7200):448–51.
CAS
PubMed
Google Scholar
Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Badminton MN, Elder GH, Holme SA, Anstey AV, Parker M, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet. 2008;83(3):408–14.
CAS
PubMed
PubMed Central
Google Scholar
Yien YY, Ducamp S, van der Vorm LN, Kardon JR, Manceau H, Kannengiesser C, Bergonia HA, Kafina MD, Karim Z, Gouya L, et al. Mutation in human CLPX elevates levels of delta-aminolevulinate synthase and protoporphyrin IX to promote erythropoietic protoporphyria. Proc Natl Acad Sci U S A. 2017;114(38):E8045–52.
CAS
PubMed
PubMed Central
Google Scholar
Schnait FG, Wolff K, Konrad K. Erythropoietic protoprophyria--submicroscopic events during the acute photosensitivity flare. Br J Dermatol. 1975;92(5):545–57.
CAS
PubMed
Google Scholar
Timonen K, Kariniemi AL, Niemi KM, Teppo AM, Tenhunen R, Kauppinen R. Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol. 2000;43(3):489–97.
CAS
PubMed
Google Scholar
Rufener EA. Erythropoietic protoporphyria: a study of its psychosocial aspects. Br J Dermatol. 1987;116(5):703–8.
CAS
PubMed
Google Scholar
Schneider-Yin X, Gouya L, Meier-Weinand A, Deybach JC, Minder EI. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr. 2000;159(10):719–25.
CAS
PubMed
Google Scholar
Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN. Erythropoietic protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol. 2006;155(3):574–81.
CAS
PubMed
Google Scholar
Balwani M, Naik H, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Overbey JR, Wang B, Singal AK, et al. Clinical, biochemical, and genetic characterization of north American patients with Erythropoietic Protoporphyria and X-linked Protoporphyria. JAMA Dermatol. 2017;153(8):789–96.
PubMed
PubMed Central
Google Scholar
Dickey A. Pitfalls and proposed solutions for patient communication about erythropoietic protoporphyria: a survey of parents and adult patients. J Am Acad Dermatol. 2019;81(5):1204–7.
PubMed
Google Scholar
Lecluse AL, Kuck-Koot VC, van WH, Sigurdsson V, Russel IM, Frank J, Pasmans SG: Erythropoietic protoporphyria without skin symptoms-you do not always see what they feel. Eur J Pediatr 2008, 167(6):703–706.
Wahlin S, Floderus Y, Stal P, Harper P. Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med. 2011;269(3):278–88.
CAS
PubMed
Google Scholar
Naik H, Overbey JR, Desnick RJ, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Wang B, Singal A, et al. Evaluating quality of life tools in north American patients with erythropoietic protoporphyria and X-linked protoporphyria. JIMD Rep. 2019;50(1):9–19.
PubMed
PubMed Central
Google Scholar
Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC, Hawk JL, Sarkany RP, McMullen E, Rhodes LE, et al. The quality of life of 790 patients with photodermatoses. Br J Dermatol. 2008;159(1):192–7.
CAS
PubMed
Google Scholar
Rutter KJ, Ashraf I, Cordingley L, Rhodes LE. Quality of life and psychological impact in the photodermatoses: a systematic review. Br J Dermatol. 2019.
Minder EI, Schneider-Yin X, Steuer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand). 2009;55(1):84–97.
CAS
Google Scholar
Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373(1):48–59.
CAS
PubMed
PubMed Central
Google Scholar
Harms JH, Lautenschlager S, Minder CE, Minder EI. Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone. Photochem Photobiol. 2009;85(6):1434–9.
CAS
PubMed
Google Scholar
Eves P, Haycock J, Layton C, Wagner M, Kemp H, Szabo M, Morandini R, Ghanem G, Garcia-Borron JC, Jimenez-Cervantes C, et al. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer. 2003;89(10):2004–15.
CAS
PubMed
PubMed Central
Google Scholar
Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581–602.
CAS
PubMed
Google Scholar
Minder EI, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and pharmacodynamics of Afamelanotide and its clinical use in treating dermatologic disorders. Clin Pharmacokinet. 2017;56(8):815–23.
CAS
PubMed
Google Scholar
Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med. 2009;360(3):306–7.
CAS
PubMed
Google Scholar
Falchetto R. The patient perspective: a matter of minutes. Patient. 2019.
Patient empowerment and access to medicines: Insights from a scientist-patient suffering from erythropoietic protoporphyria [https://journals.sagepub.com/doi/10.1177/2399202619865167].
Scenesse: EPAR - Procedural steps taken and scientific information after authorisation [https://www.ema.europa.eu/documents/procedural-steps-after/scenesse-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf (last accessed 30 May 2019)].
Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601–12.
CAS
PubMed
Google Scholar
Groot W. Adaptation and scale of reference bias in self-assessments of quality of life. J Health Econ. 2000;19(3):403–20.
CAS
PubMed
Google Scholar
Wensink D, Wagenmakers M, Barman-Aksozen J, Friesema ECH, JHP W, van Rosmalen J, Langendonk JG. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice. JAMA Dermatol. 2020;156(5):1.
Google Scholar
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
CAS
PubMed
Google Scholar
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296–310.
CAS
PubMed
Google Scholar
Murphy DA, Marelich WD, Hoffman D, Steers WN. Predictors of antiretroviral adherence. AIDS Care. 2004;16(4):471–84.
CAS
PubMed
Google Scholar
Spichty R, Balimann M, Barman J, Minder EI. A bioassay for detection of neutralizing antibodies against the alpha-melanocyte stimulating hormone analogue afamelanotide in patients with erythropoietic protoporphyria. J Pharm Biomed Anal. 2013;75:192–8.
CAS
PubMed
Google Scholar
Lengweiler S, Kreim S, Barman-Aksozen J, Maurer M, Minder EI. Evaluation of the immunogenicity of the synthetic alpha-melanocyte-stimulating hormone (alpha-MSH) analogue afamelanotide ([Nle4-D-Phe7]-alpha-MSH, Scenesse(R)) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-alpha-MSH antibodies. Skin Pharmacol Physiol. 2015;28(2):103–13.
CAS
PubMed
Google Scholar
Buckley BM. Clinical trials of orphan medicines. Lancet. 2008;371(9629):2051–5.
PubMed
Google Scholar